DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PSA 1 AND SELECT-PSA 2 STUDIES

被引：1

作者：

Cai, F. ^{[1
]}

Sornasse, T. ^{[1
]}

Ruzek, M. ^{[2
]}

Fang, Y. ^{[3
]}

Kato, K. ^{[4
]}

Wung, P. ^{[4
]}

McInnes, I. ^{[5
]}

机构：

[1] AbbVie, Precis Med Immunol, South San Francisco, CA USA

[2] AbbVie, Discovery Immunol, Worcester, MA USA

[3] AbbVie, DMPK BA, South San Francisco, CA USA

[4] AbbVie, Immunol, N Chicago, IL USA

[5] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.801

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0024

引用

页码：17 / 18

页数：2

共 5 条

[1] PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGICDMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES
Sornasse, T.
Anderson, J.
Kato, K.
Lertratanakul, A.
McInnes, I.
Ritchlin., C. T.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 433 - 433
[2] TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY
Sornasse, T.
Anderson, J.
Kato, K.
Lertratanakul, A.
Ritchlin, C. T.
McInnes, I.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 16 - 16
[3] Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
McInnes, Iain B.
Kato, Koji
Magrey, Marina
Merola, Joseph F.
Kishimoto, Mitsumasa
Pacheco-Tena, Cesar
Haaland, Derek
Chen, Liang
Duan, Yuanyuan
Zueger, Patrick
Liu, John
Lippe, Ralph
Pangan, Aileen L.
Behrens, Franck
[J]. RMD OPEN, 2021, 7 (03):
[4] Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study (vol 7, e001838, 2021)
McInnes, I. B.
Kato, K.
Magrey, M.
[J]. RMD OPEN, 2021, 7 (03):
[5] Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials
Kavanaugh, Arthur
Mease, Philip
Gossec, Laure
Ranza, Roberto
Tsuji, Shigeyoshi
Douglas, Kevin
Lane, Michael
Lippe, Ralph
Mittal, Manish
Gao, Tianming
Setty, Arathi
Ciecinski, Sandra
Aletaha, Daniel
Nash, Peter
[J]. ACR OPEN RHEUMATOLOGY, 2024,

← 1 →